ABSTRACT
Background Varicose veins represent a common cause of cardiovascular morbidity, with limited available medical therapies. Although varicose veins are heritable and epidemiologic studies have identified several candidate varicose veins risk factors, the molecular and genetic basis remains uncertain. Here, we analyzed the contribution of common genetic variants to varicose veins using data from the VA Million Veteran Program and other large multi-ancestry biobanks. Among 49,765 individuals with varicose veins and 1,334,301 disease-free controls, we identified 139 risk loci. We identified genetic overlap between varicose veins, other vascular diseases, and dozens of anthropometric factors. Using Mendelian randomization, we prioritized novel therapeutic targets via integration of proteomic and transcriptomic data. Finally, topological enrichment analyses confirmed the biologic roles of endothelial shear flow disruption, inflammation, vascular remodeling, and angiogenesis. These findings may facilitate future efforts to develop non-surgical therapies for varicose veins.
Competing Interest Statement
SMD receives research support from RenalytixAI and personal consulting fees from Calico Labs, both outside the scope of the current manuscript.
Funding Statement
MGL is supported by the Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania and the NIH/NHLBI National Research Service Award postdoctoral fellowship (T32HL007843). SMD is supported by the US Department of Veterans Affairs award #IK2-CX001780. This publication does not represent the views of the Department of Veterans Affairs or the United States Government. SMD receives research support from RenalytixAI and personal consulting fees from Calico Labs, both outside the scope of the current manuscript. DAJ, KAS, DK, MRG, ML, AMC, and JR are supported by funding from the Million Veteran Program Computational Health Analytics for Medical Precision to Improve Outcomes Now (CHAMPION) initiative and NIH grants DA051908 and DA051913. eMERGE is supported by U01HG8657 (University of Washington), U01HG8685 (Brigham and Women's Hospital)U01HG8672 (Vanderbilt University Medical Center), U01HG8666 (Cincinnati Children's Hospital Medical Center), U01HG6379 (Mayo Clinic), U01HG8679 (Geisinger Clinic), U01HG8680 (Columbia University Health Sciences), U01HG8684 (Children's Hospital of Philadelphia), U01HG8673 (Northwestern University), U01HG8701 (Vanderbilt University Medical Center serving as the Coordinating Center), U01HG8676 (Partners Healthcare/Broad Institute), and U01HG8664 (Baylor College of Medicine). This research used resources of the Oak Ridge Leadership Computing Facility, which is a DOE Office of Science User Facility supported under Contract DE-AC05-00OR22725. This manuscript has been co-authored by UT-Battelle, LLC under contract no. DE-AC05-00OR22725 with the U.S. Department of Energy. The United States Government retains and the publisher, by accepting the article for publication, acknowledges that the United States Government retains a nonexclusive, paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes. The Department of Energy will provide public access to these results of federally sponsored research in accordance with the DOE Public Access Plan: http://energy.gov/downloads/doe-public-access-plan, last accessed September 16, 2020.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The VA Million Veteran Program was approved by the VA Central Institutional Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
GWAS meta-analysis summary statistics will be deposited in dbGaP upon final publication. GWAS summary statistics from FinnGen, BioBank Japan, and UK Biobank are publicly available from https://r4.finngen.fi/, https://pheweb.jp/, and https://pan.ukbb.broadinstitute.org.
